Literature DB >> 25574925

Tuberculosis patients learning about second-hand smoke (TBLASS): results of a pilot randomised controlled trial.

N Safdar1, R Zahid1, S Shah2, R Fatima3, I Cameron4, K Siddiqi2.   

Abstract

BACKGROUND: Passive smoking is associated with tuberculosis (TB). Measures are required to protect non-smoking TB patients from second-hand smoke (SHS).
SETTING: We developed a behavioural intervention to encourage TB patients to implement smoking restrictions at home in Pakistan.
OBJECTIVES: To assess the likelihood of such an intervention being successful and to inform a definitive trial in future.
DESIGN: This was a pilot randomised controlled trial in which non-smoking TB patients were randomised to receive either individual-based support or individual-based support combined with family reminders. We recruited patients living with at least one smoker in their homes. Our primary outcome was urinary cotinine level as a measure of SHS exposure 2 months post-randomisation.
RESULTS: Of 273 patients assessed for eligibility, 150 (56%) patients were recruited and all but one were retained throughout the trial. A statistically significant absolute reduction was observed in non-smoking participants' exposure to SHS based on urinary cotinine levels in both Arm 1 (71%, 95%CI 61-79) and Arm 2 (76%, 95%CI 67-83) between baseline and follow-up at 2 months.
CONCLUSIONS: The recruitment and retention rates for trial participants make it feasible to conduct a definitive trial in future. The observed effect size makes it worthwhile to conduct such a trial.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25574925     DOI: 10.5588/ijtld.14.0615

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  1 in total

1.  Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials: Development of a Conceptual Framework.

Authors:  Sandra M Eldridge; Gillian A Lancaster; Michael J Campbell; Lehana Thabane; Sally Hopewell; Claire L Coleman; Christine M Bond
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.